Am I wrong to read this as a reference to Fusion (a recent US$1.4billion buyout by Astra Zeneca)!"... Alpha-emitter therapies, such as those involving actinium-225 (Ac-225or 225Ac) and lead-212 (Pb-212 or 212Pb), are generatinginterest,BUT;
a) Their commercialsupply chains are still in the early development phase, and they arecurrently very difficult to source.
b) They are YET TOSHOWsafety and efficacy in late-stage trials, as opposed to betaemitters, like Cu-67, that have a long history of effectiveness in treatingsolid tumors...."
If so (and I think it is) - GREAT!
Am I wrong to read this as a reference to Fusion (a recent...
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.90 |
Change
-0.060(1.52%) |
Mkt cap ! $1.212B | |||
| Open | High | Low | Value | Volume |
| $3.97 | $4.12 | $3.81 | $6.449M | 1.625M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3691 | $3.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.95 | 4000 | 1 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$3.90 |
Change
-0.060 ( 0.92 %) |
||||
| Open | High | Low | Volume | ||
| $4.00 | $4.13 | $3.81 | 99015 | ||
| Last updated 15.59pm 10/05/2024 ? | |||||
| CU6 (ASX) Chart |